New insider activity at Abeona Therapeutics ( (ABEO) ) has taken place on January 21, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Director Mark Alvino of Abeona Therapeutics has recently sold 13,500 shares of the company’s stock in a transaction valued at $70,470, signaling a notable insider move that may draw the attention of investors tracking management’s trading activity.
Spark’s Take on ABEO Stock
According to Spark, TipRanks’ AI Analyst, ABEO is a Neutral.
The score is held back mainly by weak operating performance and persistent cash burn despite a stronger balance sheet. Offsetting this, the latest earnings call reflected solid commercial and reimbursement progress for ZivaSkin, and technicals show modest near-term momentum, while valuation appears optically low but is tempered by earnings-quality concerns.
To see Spark’s full report on ABEO stock, click here.
More about Abeona Therapeutics
YTD Price Performance: 0.76%
Average Trading Volume: 1,774,807
Technical Sentiment Signal: Sell
Current Market Cap: $284.5M